Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336928 · ClinicalTrials.gov registry record
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
A clinical trial of Breast Carcinoma, sponsored by University of Southern California.
- Recruiting
- Registry status
- 490
- Enrollment target
- 4
- Study locations
NCT06336928: Recruiting study of Breast Carcinoma, sponsored by University of Southern California.
NCT06336928 is a study of Breast Carcinoma that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 490 participants, below the 766-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06336928, a study of Breast Carcinoma, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- 490 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer.
Primary Outcome
LBx results using peripheral blood samples will be compared to a pathological diagnosis of breast cancer within 1 year of the liquid biopsy test.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (4)
California
- Keck Medicine of USC Koreatown - Los Angeles
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- USC Norris Oncology/Hematology-Newport Beach - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2030-06-07 |
What NCT06336928 shows while recruiting
NCT06336928 is an observational study that tracks outcomes without assigning an intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap, below the 766-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06336928 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06336928 about?
NCT06336928 is a clinical study titled "A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis". This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer.
What is the current status of trial NCT06336928?
This trial is currently recruiting. The enrollment target is 490 participants. The study started on 2024-06-07. Estimated completion is 2030-06-07.
What conditions does trial NCT06336928 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT06336928?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06336928?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336928 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06336928's enrollment target sits among peer trials
490 21st of 106 higher than 86 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- NCT06875622 · 490 participants · NA
Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI